The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry

Nam, Sang Eun; Lim, Woosung; Lee, Jeong Eon; Lee, Seeyoun; Choi, Jin Won; Park, Heung Kyu; Jung, Yuh‐Seog; Jung, Seung Pil; Bae, Soo Youn

doi:10.1007/s10549-019-05357-y

Cited by 44 publications

(41 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past few decades, several methods have been used to clinically diagnose BC. These include breast ultrasonography, mammography, exfoliative cytology, and tumor markers that include carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), and carbohydrate antigen 153 (CA153) [4,5]. However, the sensitivity or specificity is not sufficient to screen for BC, or especially, for the early diagnosis of BC.…”

Section: Introductionmentioning

confidence: 99%

Upregulated N6-Methyladenosine RNA in Peripheral Blood: Potential Diagnostic Biomarker for Breast Cancer

et al. 2021

View full text Add to dashboard Cite

An effective biomarker for the diagnosis of breast cancer (BC) and benign breast diseases (BBD) is crucial for improving the prognosis. We investigated whether N6-methyladenosine (m 6 A) can be a diagnostic biomarker of BC. Materials and Methods We detected the contents of peripheral blood m 6 A in 62 patients with BC, 41 patients with BBD, and 41 normal controls (NCs) using the colorimetric method. The relative expression of the m 6 A regulated genes METTL14 and FTO was analyzed using quantitative real-time polymerase chain reaction. Results m 6 A in peripheral blood RNA was significantly higher in patients with BC than that in patients with BBD (p < 0.0001) or the NCs (p < 0.0001). m 6 A was closely associated with the disease stage (from stage 0 to stage I-Ⅳ; p = 0.003). The receiver operating characteristic curve of m 6 A contained an area under the curve (AUC) value of 0.887 in BC, which was greater than that of CEA or CA153. The combination of m 6 A, CEA, and CA153 improved the AUC to 0.914. The up-and downregulated mRNA expression of METTL14 and FTO, respectively, might contribute to the increase of m 6 A in patients with BC. m 6 A combined with METTL14 and FTO improved the AUC to 0.929 with a specificity of 97.4% in the peripheral blood of patients with BC. Conclusion The peripheral blood RNA of m 6 A might be a valuable biomarker for the diagnosis of BC.

show abstract

Section: Introductionmentioning

confidence: 99%

Upregulated N6-Methyladenosine RNA in Peripheral Blood: Potential Diagnostic Biomarker for Breast Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Cancer antigen 153 (CA153) is a macromolecular glycoprotein tumor marker associated with breast cancer and levels of it can be used as the best index to monitor the recurrence of breast cancer aer operation. 1,2 At present, the detection of glycoprotein tumor biomarkers is mostly by immunoassays, as they have the advantages of sensitivity and selectivity. However, the drawbacks of immunoassays, for example, the instability of the reagents and the high cost caused by the dependence on antibodies, have inuenced their further applications in clinical analysis.…”

Section: Introductionmentioning

confidence: 99%

An ionic liquid–molecularly imprinted composite based on graphene oxide for the specific recognition and extraction of cancer antigen 153

2021

View full text Add to dashboard Cite

show abstract

“…Serum-based tests have already been developed for cancer, which has been proven to be a promising noninvasive tool that aids in cancer diagnosis, disease monitoring and prognosis assessment. Serum cancer biomarkers including CEA, AFP, CA125, CA19-9 and CA15-3 have been very useful to assist cancer diagnosis and disease monitoring in various cancers 3 - 5 . However, these serum cancer biomarkers are not very useful in PC.…”

Section: Introductionmentioning

confidence: 99%

High serum CCL20 is associated with tumor progression in penile cancer

Tong

Huang

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Serum cancer biomarker has been proven to be very valuable in cancer diagnosis, disease monitoring and prognosis assessment, despite there is still a lack of serum biomarker for penile cancer (PC). Our initial analysis on public GEO dataset identified CCL20 as a top C-C motif ligand (CCL) gene enriched in PC. The patients with PC exhibited markedly higher preoperative serum CCL20 level than healthy control. The area under the curve (AUC) was 0.855 with the sensitivity of 72.4%, and specificity of 93.5% to distinguish PC. Preoperative serum CCL20 level was significantly associated with clinicopathological characteristics including T stage ( P =0.005), nodal status ( P =0.008), and pelvic lymph node metastasis ( P =0.007). PC Patients with high serum CCL20 level had shorter disease-free survival compared to those with low level ( P <0.001). Cox regression analysis showed that serum CCL20 level could serve as an independent prognostic factor for disease-free survival with a HR of 3.980 (95% CI: 1.209-13.098, P =0.023). Furthermore, CCL20 expression was observed in PC tissues and cell lines. Knockdown of CCL20 expression markedly suppressed malignant phenotypes (cell proliferation, clonogenesis, apoptosis escape, migration and invasion), attenuated STAT3 and AKT signaling and reduced MMP2/9 secretion in PC cell lines. Consistently, CCL20 and its receptor CCR6 exhibited correlated expression pattern in PC tissues. In conclusion, serum CCL20 level might serve as a potential diagnostic and prognostic cancer biomarker for PC. CCL20 might activate multiple downstream oncogenic signaling pathways (STAT3, AKT, MMP2/9) to promote malignant progression of PC, which may warrant further investigation in the future.

show abstract

The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry

Cited by 44 publications

References 32 publications

Upregulated N6-Methyladenosine RNA in Peripheral Blood: Potential Diagnostic Biomarker for Breast Cancer

Upregulated N6-Methyladenosine RNA in Peripheral Blood: Potential Diagnostic Biomarker for Breast Cancer

An ionic liquid–molecularly imprinted composite based on graphene oxide for the specific recognition and extraction of cancer antigen 153

High serum CCL20 is associated with tumor progression in penile cancer

Contact Info

Product

Resources

About